| 摘要 |
The present invention relates to a refined and detailed molecular model of the E2F1 integrin l-domain, especially the MIDAS and to the use of such a model for designing novel integrin modulators, especially E2F1 integrin modulators. The present invention further relates to novel E2F1 I-domain modulators, which are of therapeutic potential. The present invention further relates to specific families of small molecule modulators interacting with collagen receptors, tetracyclic polyketides and sulfonamides. The present invention further relates to the use of such modulators for the manufacture of medicaments for thrombosis, inflammation and/or cancer.
|
